Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1432-1440
    Keywords: Fibrates ; Postprandial lipemia ; Chylomicrons ; Lipoprotein lipase ; High-density lipoproteins
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract In 11 patients with 1113 hyperlipoproteinemia we studied fasting lipids, lipoproteins, lipoprotein-modifying enzymes, and postprandial lipid metabolism after a standardized oral fat load supplemented with vitamin A before and 12 weeks after treatment with fenofibrate, a third-generation fibric acid derivative. Fasting plasma cholesterol, triglycerides, low-density lipoprotein cholesterol decreased significantly (P 〈 0.05, P 〈 0.01, P 〈 0.01), high-density lipoprotein subfraction 3 cholesterol increased significantly (P 〈 0.05), and high-density lipoprotein subfraction 2 cholesterol remained unchanged. Postprandial lipemia, i.e., the integrated postprandial triglyceride concentrations corrected for the fasting triglyceride level, and postprandial chylomicron concentrations, as assessed by biosynthetic labeling of chylomicrons with retinyl palmitate, decreased by 40.6% and 60.1% (P 〈 0.05; P 〈 0.05), respectively. The activity of lipoprotein lipase (LPL) increased by 33.6% (P 〈 0.05); the increase in LPL during fenofibrate treatment was positively correlated with the increase in high-density lipoprotein cholesterol (r = 0.84; P 〈 0.005). Hepatic lipase and cholesteryl ester transfer protein mass and activity remained unchanged. We conclude that lipid-lowering therapy with fenofibrate ameliorates fasting and, more profoundly, postprandial lipoprotein transport in hypertriglyceridemia by curbing postprandial triglyceride and chylomicron accumulation, at least in part, through an increase in LPL activity.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 55 (1977), S. 1025-1030 
    ISSN: 1432-1440
    Keywords: Hypercholesterinämie ; Hypertriglyzeridämie ; Dyslipoproteinämie ; Ultrazentrifugation ; Lipoproteinelektrophorese ; Hypercholesterolemia ; Hypertriglyceridemia ; Dyslipoproteinemia ; Ultracentrifugation ; Lipoprotein Electrophoresis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary Familial type III hyperlipoproteinemia is characterized by the presence of elevated plasma levels of very low density lipoproteins (VLDL) which contain an increased amount of cholesterol and by the presence of a significant amount of lipoproteins with an intermediate density between that of VLDL and low density lipoproteins (LDL); the intermediate density lipoproteins, designated IDL or Lp III, have a slower electrophoretic migration rate than VLDL, and are found in the ultracentrifugal top fraction as a contaminant. Classically, the diagnosis of type III is based on the demonstration of beta-migrating lipoproteins in the ultracentrifugal top fraction (density 〈1.006), thus “floating beta-lipoprotein”. More recently, it has been proposed that an elevated VLDL-cholesterol to triglyceride ratio is diagnostic of the disorder. In the present report, we have compared the two methods for their diagnostic value and have concluded that the chemical index definition is the more reliable method for the diagnosis of type III hyperlipoproteinemia.
    Notes: Zusammenfassung Die familiäre Hyperlipoproteinämie Typ III ist gekennzeichnet durch 1) einen erhöhten Plasmaspiegel von Lipoproteinen sehr niederer Dichte (Verylowdensitylipoproteins, VLDL), welche ungewöhnlich cholesterinreich sind, und 2) durch Plasmalipoproteine mit einer Dichte zwischen der von VLLL und Lipoproteinen niederer Dichte (Lowdensitylipoproteins, LDL); diese Lipoproteine mit „Zwischendichte“ (Intermediatedensitylipoproteins, IDL oder Lp III) wandern elektrophoretisch langsamer als VLDL und werden als Verunreinigung in den in der Ultrazentrifuge flotierenden VLDL (Dichte 〈1006) gefunden. Allgemein wird die Diagnose der Hyperlipoproteinämie Typ III durch den Nachweis von Lipoproteinen gestellt, welche mit VLDL flotieren, aber elektrophoretisch mit beta-Globulinen wandern (“floating beta-lipoprotein”). Neuerlich wurde ein erhöhtes Verhältnis von VLDL-Cholesterin zu Plasmatriglyzeriden höher als 0,30 als diagnostisch für die Erkrankung beschrieben. Wir haben die beiden Methoden zur Diagnosestellung verglichen und kamen zu dem Schluß, daß die chemische Indexdefinition in der Diagnosestellung der Hyperlipoproteinämie Typ III verläßlicher ist.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...